Markowitz, Samuel N; Devenyi, Robert G; Munk, Marion; Croissant, Cindy L; Tedford, Stephanie E; Rückert, Rene; Walker, Michael G; Patino, Beatriz E; Chen, Lina; Nido, Monica; Tedford, Clark E (2020). A DOUBLE-MASKED, RANDOMIZED, SHAM-CONTROLLED, SINGLE-CENTER STUDY WITH PHOTOBIOMODULATION FOR THE TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATION. Retina - the journal of retinal and vitreous diseases, 40(8), pp. 1471-1482. Lippincott, Williams & Wilkins 10.1097/IAE.0000000000002632
|
Text
Markowitz et al., Retina, 2019.pdf - Published Version Available under License Publisher holds Copyright. Download (744kB) | Preview |
PURPOSE
The LIGHTSITE I study investigated the efficacy and safety of photobiomodulation (PBM) treatment in subjects with dry age-related macular degeneration.
METHODS
Thirty subjects (46 eyes) were treated with the Valeda Light Delivery System, wherein subjects underwent two series of treatments (3× per week for 3-4 weeks) over 1 year. Outcome measures included best-corrected visual acuity, contrast sensitivity, microperimetry, central drusen volume and drusen thickness, and quality of life assessments.
RESULTS
Photobiomodulation-treated subjects showed a best-corrected visual acuity mean letter score gain of 4 letters immediately after each treatment series at Month 1 (M1) and Month 7 (M7). Approximately 50% of PBM-treated subjects showed improvement of ≥5 letters versus 13.6% in sham-treated subjects at M1. High responding subjects (≥5-letter improvement) in the PBM-treated group showed a gain of 8 letters after initial treatment (P < 0.01) and exhibited earlier stages of age-related macular degeneration disease. Statistically significant improvements in contrast sensitivity, central drusen volume, central drusen thickness, and quality of life were observed (P < 0.05). No device-related adverse events were reported.
CONCLUSION
Photobiomodulation treatment statistically improved clinical and anatomical outcomes with more robust benefits observed in subjects with earlier stages of dry age-related macular degeneration. Repeated PBM treatments are necessary to maintain benefits. These pilot findings support previous reports and suggest the utility of PBM as a safe and effective therapy in subjects with dry age-related macular degeneration.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Ophthalmology |
UniBE Contributor: |
Munk, Marion |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0275-004X |
Publisher: |
Lippincott, Williams & Wilkins |
Language: |
English |
Submitter: |
Marion Munk |
Date Deposited: |
28 Aug 2019 15:06 |
Last Modified: |
05 Dec 2022 15:30 |
Publisher DOI: |
10.1097/IAE.0000000000002632 |
PubMed ID: |
31404033 |
BORIS DOI: |
10.7892/boris.132625 |
URI: |
https://boris.unibe.ch/id/eprint/132625 |
Actions (login required)
 |
Edit item |